Risk stacking of pneumococcal vaccination indications increases mortality in unvaccinated adults with Streptococcus pneumoniae infections
Introduction
Serious Streptococcus pneumoniae infections, including pneumonia, bacteremia, and meningitis, are a major cause of morbidity and mortality among older adults [1], [2], [3]. Since the 1980s, vaccines to prevent pneumococcal disease have been used on a global scale to mitigate the risks associated with these bacterial infections [4]. The Advisory Committee on Immunization Practices (ACIP) recommends administration of the pneumococcal vaccination to adults with certain risk factors for pneumococcal disease, including age ≥ 65 years, alcoholism, heart disease and heart failure, chronic respiratory disease, hepatic dysfunction, immunodeficiency, and smoking, in an effort to prevent invasive pneumococcal disease (IPD) and subsequent poor outcomes [3].
Recent research has revealed that the presence of multiple, concomitant risk factors (risk stacking), particularly those conditions identified by ACIP as indications for pneumococcal vaccination, increases the likelihood of developing pneumococcal disease beyond the risk posed by individual risk factors alone [5], [6]. As our population ages, it is becoming more common for patients to have two or more risk factors [6]. However, the impact of risk stacking on outcomes, namely mortality, of adults who end up developing pneumococcal disease remains unknown. Furthermore, current data on risk stacking are limited in that there is no information regarding the impact of risk stacking “at-risk” conditions (e.g., alcoholism, heart disease, liver disease, cigarette smoking) with “high-risk” conditions (e.g., immunodeficiency) [5], [6], [7]. As such, the purpose of this study was to quantify the impact of stacking risk factors for developing pneumococcal disease on 30-day mortality among unvaccinated older adults.
Section snippets
Methods
Using national Veterans Health Administration databases, we conducted a nested case-control study of older Veterans (age ≥ 50 years) with positive S. pneumoniae blood, cerebrospinal fluid, or respiratory cultures between January 1, 2002 and December 31, 2011. We defined serious pneumococcal infections as culture-positive pneumonia, bacteremia, and meningitis. Cases were those individuals who died from any cause within 30 days of positive culture, and controls were those alive at 30 days. Patients
Results
We identified 9730 serious pneumococcal infections in 9468 unvaccinated individuals, with a 30-day mortality rate of 18.6% (1764 cases and 7966 controls; Table 1). The primary infection types, determined from positive cultures, included pneumonia (cases n = 871, 49.4%; controls n = 5204, 65.3%), bacteremia (cases n = 585, 33.2%; controls n = 1969, 24.7%), and bacteremic pneumonia (cases n = 305, 17.3%; controls n = 755, 9.5%). Meningitis accounted for <1% of infections among cases and among controls.
There
Discussion
We quantified the impact of stacking pneumococcal disease risk factors on 30-day mortality in unvaccinated older Veterans with serious pneumococcal infections. Of the 8 individual risk factors assessed, 37.5% of them significantly increased the risk of death and of the 247 stacked risks, 35% significantly increased the risk of death. Current literature regarding predictors of mortality in the setting of pneumococcal disease is primarily related to the impact of individual predictors,
Conclusion
In unvaccinated older Veterans with serious pneumococcal disease, the presence of multiple ACIP risk factors for developing pneumococcal disease was associated with higher 30-day all-cause mortality. The more indications for vaccination present, the greater the risk of death, which was almost three times higher among those with six stacked risk factors as opposed to a single risk factor. As multiple risk factors for pneumococcal disease are common among older adults, effective vaccination
Funding
This study was supported, in part, by an Advancing Science through Pfizer Initiated Research (ASPIRE) grant from Pfizer Inc.
Conflict of interest
Jacob Morton has no reported financial relationships relevant to this article. Haley Morrill has received research funding from Merck. Kerry LaPlante has received research funding and/or served as a scientific advisor or consultant for Merck (Cubist), BARD/Davol, Allergan (Forest Laboratories and Durata Therapeutics), The Medicines Company, and Pfizer Inc. Aisling Caffrey has received research funding from Pfizer Inc, Merck (Cubist), and The Medicines Company.
Acknowledgement
The views expressed are those of the authors and do not necessarily reflect the position or policy of the United States Department of Veterans Affairs. This material is based upon work supported, in part, by the Office of Research and Development, Department of Veterans Affairs. JBM was supported by Office of Academic Affiliations, Department of Veterans Affairs, and HJM is supported in part by a VA New England Career Development Award.
References (26)
- et al.
Redefining risk categories for pneumococcal disease in adults: critical analysis of the evidence
Int J Infect Dis
(2015) - et al.
Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995–2011
Vaccine
(2013) - et al.
Comparison of clinical features, antimicrobial susceptibility, serotype distribution and outcomes of patients with hospital- and community-associated invasive pneumococcal disease
Int J Antimicrob Agents
(2010) - et al.
Adults with invasive pneumococcal disease: missed opportunities for vaccination
Am J Prev Med
(2006) - et al.
Epidemiology of pneumococcal disease in a national cohort of older adults
Infect Dis Ther
(2014) - et al.
Streptococcus pneumoniae
Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
MMWR Morb Mort Wkly Rep
(2014)Pneumococcal vaccines WHO position paper
Wkly Epidemiol Record
(2012)- et al.
Rethinking risk for pneumococcal disease in adults: the role of risk stacking.
Open Forum Infect Dis
(2015) - et al.
Rates of pneumococcal disease in adults with chronic medical conditions
Open Forum Infect Dis
(2014)
Clinical features and prognostic factors in adults with bacterial meningitis
N Engl J Med
Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries
J Infect Dis
Host factors and biomarkers associated with poor outcomes in adults with invasive pneumococcal disease
PLoS ONE
Cited by (19)
Improving Immunization Coverage in Special Populations
2020, Primary Care - Clinics in Office PracticeCitation Excerpt :Heart disease, cancer, stroke, chronic obstructive pulmonary disease, and diabetes are the most common chronic diseases, and 25% of adults have 2 or more conditions, with the number of comorbidities increasing with age.1 In a cohort of adults aged 50 years and older with serious pneumococcal infection who were not immunized for pneumococcal disease, 30-day mortality risk increased based on the number of indications present for immunization by 55% for each indication.2 Health care providers (HCPs) are a special population worthy of consideration on their own.
Adult invasive pneumococcal disease in the Republic of Korea: Risk medical conditions and mortality stratified by age group
2018, International Journal of Infectious DiseasesCitation Excerpt :A recent study reported that the relative risk of IPD incidence in group 2 (50–64 years) was twice that in group 1 (18–49 years), as one or more IPD-disposing medical comorbidities occur more frequently after the age of 50 years (Baxter et al., 2016). An additional study has determined that multiple risk factors (stacked risks) for pneumococcal disease increase the 30-day mortality among adults aged ≥50 years with severe pneumococcal disease (Morton et al., 2017). However, in the present study, no other underlying CCs of pneumococcal vaccination indications, single or stacked, were found to be significant risk factors for mortality in the overall patients or analyses according to age groups, probably due to a similar distribution of these underlying comorbidities between survivors and non-survivors.
Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18–49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors
2023, Human Vaccines and ImmunotherapeuticsMissed Pneumococcal Vaccination Opportunities in Adults With Invasive Pneumococcal Disease in a Community Health System
2022, Open Forum Infectious Diseases